

**CURRICULUM VITAE**  
**LIST OF PUBLICATIONS**

---



PD Dr. rer. nat. NATALIA S.PELLEGATA

March 2016

**PERSONAL DATA**

---

Name: Natalia S. Pellegata  
 Date of birth: 22/07/1966  
 Place of birth: Milan, Italy  
 Academic title: Priv. Doz. Dr. rer. nat.

**Current position (2007-):** Head of the Neuroendocrine Cell Transformation and Dysfunction Group  
 Institut für Pathologie, Helmholtz Zentrum München  
 Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH).

Address: Institut für Pathologie, Helmholtz Zentrum München  
 Ingoldstädter Landstraße 1, 85764 Neuherberg  
 Phone: +49-(0)89-3187 2633  
 E-mail: [natalia.pellegata@helmholtz-muenchen.de](mailto:natalia.pellegata@helmholtz-muenchen.de)

**EDUCATION**

---

Bachelor's degree	1980-1985	High School "G.B. Vico", Corsico, Milan, Italy (Note: 60/60)
Master's Degree	1985-1989	University of Pavia, Italy, Faculty: Biology Dissertation on: "Proto-oncogene amplification in gastric cancer: 50 samples analyzed for c-myc, c-erbB2, c-Ki-ras, c-N-ras, hst, c-mos" Institute of Genetic and Microbiology, University of Pavia, Italy. (Supervisor: Prof. G.N. Ranzani). Grade: 110/110 <i>summa cum laude</i>
Ph.D.	1989-1993	Institute of Genetic and Microbiology, University of Pavia, Italy. Topic: Cancer Genetics. PhD Thesis on: "Genetic lesions in pancreatic tumors: mutations of the proto-oncogene K-ras and of the p53 tumor suppressor gene". Institute of Genetic and Microbiology, University of Pavia, Italy. (Mentor: Prof. G.N. Ranzani)
Licence (Biologist)	1995	University of Pavia, Italy
Habilitation	2010	Faculty of Medicine, Technical University Munich Subject: Molecular Pathology.

**PREVIOUS APPOINTMENTS**

---

1993-1995	Post-doctoral fellow.	Department. of Microbiology and Molecular Genetics, University of California at Irvine, Irvine, CA, USA. Supervisor: Prof. Eric J. Stanbridge.
1995- 1998	Post-doctoral fellow.	Department of Genetics and Microbiology, University of Pavia. Supervisor: Prof. Guglielmina N. Ranzani.
1998- 2000	Post-doctoral fellow.	Human Cancer Genetics Division, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio. Supervisor: Prof. Dr. Albert de la Chapelle.

- 2000-2002     Research Scientist.     Human Cancer Genetics Division, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio.
- 2001-2011     Adjunct Assistant Professor.     Department of Molecular Virology, Immunology and Medical Genetics, College of Medicine, Ohio State University, Columbus, Ohio.
- 2002-2007     Senior Scientist .     Institut für Pathologie, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH). Group of Dr. Michale J. Atkinson.

## FELLOWSHIPS, AWARDS and HONOURS

---

- Erasmus Fellowship for an exchange with the Leiden University (stage at the Sylvius Laboratories), The Netherlands (1991)
- Travel award of the Italian National Research Council (CNR) (1993)
- International Cancer Technology Transfer Fellowships (ICRETT) of the Union for International Cancer Control (UICC) to work at the University of California Irvine (1993)
- International Fellowship from the Italian Association for Cancer Research (AIRC) to work at the University of California Irvine (1993-1994)
- Fellowship from the Coordinating Committee of the Universities of California to continue working at the University of California Irvine (1994-1995)
- Travel award from the American Association for Cancer Research (AACR) (1994)
- Post-Doctoral fellowship from the University of Pavia (1995-1997)
- American Cancer Society International Fellowship for Beginning Investigators (ACSBI-IUCC) to work at the Ohio State University (1998-1999)
- American Italian Cancer Society Fellowship for Cancer Research to continue working at the Ohio State University (1999-2000)
- Short Visit Grant of the European Science Foundation-European Network for the Study of Adrenal Tumours (ENS@T) for a collaboration with the CNRS, Valbonne, France (2014)
- International Cancer Technology Transfer Fellowship from the Union for International Cancer Control (UICC) for a collaborative project with the Ohio State University (2014)
- "Eleonore Trefftz Visiting Professorship" for women scientists (University of Dresden; 2015)

## PROFESSIONAL ACTIVITIES

---

- Appointed to the committee for the external evaluation of the KFO 252 "Microenvironment of the Adrenal in Health and Disease" by the Deutsche Forschungsgemeinschaft (DFG) (in 2011 and 2014)
- Member of the Regional Scientific Committee for the "IWMEN 2012" international workshop on multiple endocrine neoplasia (2012)
- Ad Hoc Scientific reviewer: Cancer Research; PlosOne; Cancer Letters; Endocrine-related Cancers; Journal of Clinical Endocrinology and Metabolism; Molecular and Cellular Endocrinology; European Journal of Endocrinology

- Ad Hoc International Grant Reviewer: Agence Nationale de la Recherche (ANR), France; Association for International Cancer Research (AICR), United Kingdom; Institut National de la Santé et de la Recherche Médicale (Inserm), France

## MEMBERSHIP to SCIENTIFIC ASSOCIATIONS

---

- Since 1998 Union for International Cancer Control (UICC)
- Since 2000 American Association for Cancer Research (AACR)
- Since 2006 European Neuroendocrine Tumors Society (ENETS)
- Since 2012 European Society of Endocrinology (ESE)
- Since 2013 European Network for the Study of Adrenal Tumours (ENS@T)

## ACADEMIC/EDUCATIONAL ACTIVITIES

---

- Academic Host for Prof. Clara Bloomfield, MD, Distinguished University Professor at Ohio State and senior advisor to The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, (in 2010 and 2011)
- PhD Thesis committee member of Yashodhara Ingawale, Institute of Radiation Biology, Helmholtz Zentrum München (2013-)
- International PhD thesis committee member of Katiuscia Benfani, "Dottorato in Scienze Biomediche", University of Ferrara, Italy (2013-2016).

## TEACHING

---

- 1995-1996 Lecturer. Graduate School in Applied Genetics at the Dept. of Genetics and Microbiology, University of Pavia, Italy. Topic: the regulation of cell cycle progression
- 1995-1997 Laboratory Instructor. Faculty of Biological Sciences, University of Pavia, Italy. Topics: the molecular techniques required to accomplish the practical within the "Experimental Biology (Genetics)" course
- 1997-1998 Lecturer. Twenty lectures to students of Biological Sciences at the University of Pavia, Italy, as part of the "Molecular Biology" course. Topics: oncogenes and tumor suppressor genes; the two hit hypothesis for tumor suppressor genes inactivation; RB and p53; mutational spectra of p53; structure-function relations for p53 gene mutations; p53-mediated apoptosis
- 2001 Guest lecturer. Graduate School in Applied Genetics at the Dept. of Genetics and Microbiology, University of Pavia, Italy. Topics: the possible applications of DNA microarrays in human genetics, cancer genetics, cancer classification
- 2012 Guest lecturer. PhD Program in "Genetics, Molecular and Cellular Biology", University of Pavia, Italy. Topic: The molecular pathogenesis of neuroendocrine tumors (NETs); the MENX model to study NETs
- 2013-2014 Lecturer. Graduate School in "Molecular Radiation Carcinogenesis", HMGU, Institute of radiation Biology. Topics: Cell cycle regulation in normal and cancer cells; The RET gene in radiation-induced and syndromic endocrine tumors.
- Since 2008 Lectures in the "Molecular Pathology" series (TU-München). Topic: The cell cycle

Since 2008 Lectures in the “Organ-specific Molecular Carcinogenesis” series (TU-München). Topic: The molecular pathology of endocrine tumors

## MENTORING

---

High School students (Europäische Schule München “Praktikum”): Barbara Cristiani; Lorenzo Cristiani; Sara Donati; Anna Yevtuschenko; Miriana Coluzzi; Claudio Capasso; Leyla Lorenz; Ridhi Pandit; Mara Kießling; Paolo Donati; Francesco Orlandi; Matteo Luciani; Marta Balestra; Beatrice Cristiani; Sofia Piermarini.

Undergraduate students (University “Praktikum”): Antonia Saint Paul (2008); Kathrin Schmohl (2010); Steffeni Mountford (2010); Ewelina Zmyslowska (2011); Ninelia Minaskan (2012); Christina Shug (2012); Felix Hilfreich (2013); Katharina Buhl (2013); Corinna Schindler (2015); Laura Flüter (2016)

Undergraduate students (Master’s Thesis): Flavio Chiaino (1997); Sebastian Schwarz (2005); Evi Kiermaier (2006); Christian Jung (2008); Stephanie Bergmoser (2009); Kathrin Schmohl (2010); Nikolai Falk (2010); Steffeni Mountford (2011); Ines Repokis (2011); Ewelina Zmysloska (2012); Ninelia Minaskan (2013); Katharina Buhl (2014); Vanessa Nkam (2016)

Graduate students (Ph.D.): Ying Huang (1998-2001); Heejei Yoon (1999-2002); Alena Shilo (2004-2008); Misu Lee (2008-2011); Nikolai Falk (2011-2015); Ines Repokis (2012-2015); Ninelia Minaskan (2013- ); Andrea Richter (2013- ); Eva-Maria Planitscher (2015- ).

## INDEPENDENT FUNDING

---

### Current

- *Deutsche Krebshilfe*. “Identification of new molecular markers for the diagnosis and prognosis of human neuroendocrine tumors” (2008-2009). [83.600 Eur]  
**Renewed : 2010-2013 [240.000 Eur]**  
**Renewed : 2013-2016 [245.000 Eur]**
- *DFG-SFB 824*. “Characterization of an *in-vivo* model of multiple endocrine neoplasia for development of targeted drugs and early response monitoring using molecular imaging”. (2009-2013) [522.500 Eur]  
**2<sup>nd</sup> funding period: 2013-2017 [400.000 Eur]**
- *Wilhelm Sander Stiftung* “The role of angiogenesis-related proteins in pituitary adenomas”. (2015-2017) [120.000 Eur]
- **Scientific cooperation with Novartis Oncology, GmbH (since 2009, 10.000 Eur/year)**

### Previous

- *Seed grant-Program of the Ohio State University, Ohio, USA* (Institutional Research Grant from the American Cancer Society #IRG-98-278-02) “Gene expression profiling of papillary thyroid carcinoma.” (2002). [20.000 \$]
- *DAAD- People Exchange Program (PPP)* “Genetic predisposition to neuroendocrine cancers: from animal models to human patients”. Collaboration with the University of Pavia, Italy (2007-2008) [20.000 Eur]

- *EUMODIC*. “Mouse cancer models”. (2008-2011) [60.000 Eur]
- *DAAD- People Exchange Program (PPP)* “Exploring the role of *CDKN1B* (p27) in the predisposition to multiple neuroendocrine tumors”. Collaboration with the University of São Paulo, Brazil (2010-2012) [20.000 Eur]
- *Wilhelm Sander Stiftung* “BMP dependent mechanisms in adrenomedullary tumorigenesis“. (2012-2014) [160.000 Eur]

## INVITED RESEARCH PRESENTATIONS

---

- “Detection of K-ras mutations by denaturing gradient gel electrophoresis: a study on pancreatic cancer”. Special International Symposium “Cancer as a Genetic Disease”. Rome, May 1992.
- “DNA damage and p53-mediated cell cycle arrest: a reevaluation”. The 9th International Conference of the International Society of Differentiation “Development, Cell Differentiation and Cancer”. Pisa, September 1996.
- “p53 and radiation-induced cell cycle arrest”. MTC Karolinska Institute, Stockholm, Sweden, October 17, 1997.
- “Searching for the gene responsible for cornea plana congenita”. 10<sup>th</sup> Annual Stone Lab. Meeting, the Ohio State University Comprehensive Cancer Center, Put-in-Bay, OH. September 18-20, 1998.
- “Keratocan, a small leucine-rich proteoglycan gene, in the causation of cornea plana”. Human Cancer Genetics Seminar Series, the Ohio State University. March 15, 2000.
- “Identification of the genes involved in papillary thyroid carcinoma”. GSF- National Research Center for Environment and Health, Institute of Pathology, Munich-Neuherberg, Germany, November 12, 2002.
- “Search for New Genes Involved in Papillary Thyroid Carcinoma”. PhD program-Lecture series, GSF-Klinikum Großhadern, May 3, 2004.
- “An MEN-like syndrome in the rat provides evidence of a new genetic mechanism, of neuroendocrine tumorigenesis”. 95<sup>th</sup> Annual Meeting of the American Association for Cancer Research (AACR). Orlando, FL, March 31, 2004.
- “An animal model of multiple endocrine neoplasia”. Department of Genetics and Microbiology, University of Pavia, Italy, February 27, 2007.
- “MENX”. Workshop: Hereditary predisposition in pituitary adenomas: from bench to bedside. Hospital ca’ Foncello, Treviso, Italy, September 28, 2007.
- “Animal models in NET disease: Lessons from p27Kip1 expression”. 5<sup>th</sup> Annual Conference of the European Neuroendocrine Tumor Society (ENETS), Paris, France, 7 March 2008.
- “p27Kip1 gene- a new (rare) MEN1 gene”. MEN2008, 11<sup>th</sup> International Workshop on Multiple Endocrine Neoplasia, Delphi, Greece, September 26, 2008.
- “What is the MENX syndrome”. 135<sup>th</sup> Meeting of the European Neuroendocrine Association (ENEA), Antalya, Turkey, October 19, 2008.
- “The discovery of MEN4 and the role of *CDKN1B*”. FIPA 2009, Workshop on Genetic, Molecular and Clinical Aspects of Familial Pituitary Adenoma, Liège, Belgium, May 8, 2009.
- “What can MENX-rats teach us about NET tumorigenesis?” Annual Meeting of the German Society of Endocrinology, DGE 2010, Leipzig, Germany, March 6, 2010.
- “MENX-associated pheochromocytoma”. MEN2010, 12<sup>th</sup> International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, September 18, 2010.
- “MEN4: recent advances on p27 pathophysiology?” 136<sup>th</sup> Meeting of the European Neuroendocrine Association (ENEA), Liège, Belgium, September 24, 2010.

- “Lessons from MENX” 13<sup>th</sup> European Congress of Endocrinology (ECE2011), Rotterdam, The Netherlands, May 1, 2011.
- “MENX-associated rat pheochromocytoma” 3<sup>rd</sup> International Symposium on Pheochromocytoma, ISP2011, Paris- Marne La Vallee, France, September 16, 2011.
- “MENX from the lab to the clinics”. Annual Dutch Endocrine Meeting 2012, Noordwijkerhout, The Netherlands, February 11, 2012.
- “MENX” 55<sup>èmes</sup> Journées Internationales d’Endocrinologie Clinique Henri-Pierre Klotz, Paris, France, May 31, 2012.
- “Does a new mutation always predict a new disease ? Lessons from p27”. 15<sup>th</sup> European Congress of Endocrinology (ECE2013), Copenhagen, Denmark, May 1, 2013.
- “The rat MENX syndrome as a platform for translational studies of neuroendocrine tumors”. Lecture series at the Institute of Pathology, University of Tübingen, June 6, 2013.
- “MENX-associated rat thyroid lesions”. Lecture series at the Division of Human Cancer Genetics, Dept. of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Ohio. October 2013.
- “The rat MENX syndrome: pancreatic islet cell hyperplasia and associated phenotypic features”. Lecture series KFO 252, University of Dresden, February 11, 2014.
- “MENX as model of development of NET: from hyperplasia to carcinoma”. 16th Meeting of the European Neuroendocrine Association (ENEA), Sofia, Bulgaria, September 13, 2014.
- “p27 mutations and syndromic pituitary adenomas: an update”. 4th ENEA (European Neuroendocrine Association) Workshop on Acromegaly, Marseilles, France, December 11, 2015.
- “Molecular mechanisms involved in the pathogenesis of gonadotroph adenomas”. 19th Annual Meeting of the Neuroendocrinology Section of the German Society for Endocrinology (DGE). Munich, Germany, November 20<sup>th</sup>, 2015.

## LIST OF PEER-REVIEWED PUBLICATIONS

---

### FULL PAPERS

- 1) Ranzani GN, **Pellegata NS**, Previderè C, Saragoni A Vio A, Maltoni M and Amadori D. (1990) Heterogeneous proto-oncogenes amplification correlates with tumor progression and presence of metastases in gastric cancer patients. *Cancer Res.* 50, 7811-7814.
- 2) **Pellegata NS**, Bergamaschi G, Amadori D, Aloia A, Ballarini P, Del Senno L, Amaducci L and Ranzani GN. (1991) A 5'-truncated c-myc gene variant not associated with a risk of cancer. *Hum. Genet.* 87, 579-582.
- 3) **Pellegata NS**, Losekoot M, Fodde R, Pugliese V, Saccomanno S, Renault B, Bernini LF and Ranzani GN. (1992) Detection of K-ras mutations in exocrine pancreatic cancer by denaturing gradient gel electrophoresis (DGGE). *Anticancer Res.* 12, 1731-1736.
- 4) Renault B, Van den Broek M, Fodde R, Wijnen J, **Pellegata NS**, Amadori D, Khan MP and Ranzani GN. (1993) Base transitions are the most frequent genetic changes at P53 in gastric cancer. *Cancer Res.* 53, 2614-2617.
- 5) De Benedetti L, Varesco L, **Pellegata NS**, Losi L, Gismondi V, Casarino L, Sciallero S, Bonelli L, Biticchi R, Bafico A, Masetti E, James R, Heouaine A, Ranzani GN, Aste H and Ferrara G. (1993) Genetic events in sporadic colorectal adenomas: K-ras and p53 heterozygous mutations are not sufficient for malignant progression. *Anticancer Res.* 13, 667-670.
- 6) Ranzani GN, Renault B, **Pellegata NS**, Fattorini P, Magni E, Bacci F and Amadori D. (1993) Loss of heterozygosity and K-ras gene mutations in gastric cancer. *Hum. Genet.* 92, 244-249.
- 7) **Pellegata NS**, Sessa F, Renault B, Bonato M, Leone BE, Solcia E and Ranzani GN. (1994) K-ras and P53 gene mutations in pancreatic cancer: ductal and non-ductal tumors progress through different genetic lesions. *Cancer Res.* 54, 1556-1560.

- 8) Silini, E., Bosi, F., **Pellegata NS**, Romano, A.M., Volpato, G., Romano, A., Nazari, S., Tinelli, C., Ranzani, G.N., Solcia, E. and Fiocca, R. (1994) K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. *Virchows Archiv.* 424, 367-373.
- 9) Tenti P, Romagnoli S, **Pellegata NS**, Zappatore R, Giunta P, Ranzani GN and Carnevali L. (1994) Primary retroperitoneal mucinous cystadenocarcinomas: immunohistochemical and molecular study. *Virchows Archiv.* 424, 53-57.
- 10) Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, **Pellegata NS**, Ranzani GN, Rickaert F, Kloppel G. (1994) Intraductal papillary-mucinous tumors represent a distinct group of pancreatic neoplasms: an investigation of tumor cell differentiation and K-ras, p53 and c-erbB2 abnormalities in 26 patients. *Virchows Archiv.* 425, 357-367.
- 11) Tenti P, Romagnoli S, Silini E, **Pellegata NS**, Zappatore R, Spinillo A, Zara C, Ranzani GN and Carnevali L. (1995) Analysis and clinical implications of K-ras gene mutations and human papillomavirus infection in primary adenocarcinoma of the uterine cervix. *Int. J. Cancer* 64, 9-13.
- 12) **Pellegata NS**, Cajot J-F and Stanbridge EJ. (1995) The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. *Oncogene* 11, 337-349.
- 13) Chen WH, **Pellegata NS** and Wang PH. (1995) Coordinated effects of insulin-like growth factor I on inhibitory pathways of cell cycle progression in cultured cardiac muscle cells. *Endocrinology* 136, 5240-5243.
- 14) Campomenosi P, Ottaggio L, Moro F, Urbini S, Bogliolo M, Zunino A, Camoriano A, Inga A, Gentile SL, **Pellegata NS**, Bonassi S, Bruzzone E, Iannone R, Pisani R, Menichini P, Ranzani GN, Bonatti S, Abbondandolo A and Fronza G. (1996) Study on aneuploidy and p53 mutations in astrocytomas. *Cancer Genet. and Cytogenet.* 88, 95-102.
- 15) **Pellegata NS**, Antoniono RJ, Redpath JL and Stanbridge EJ. (1996) DNA damage and p53-mediated cell cycle arrest: a reevaluation. *Proc. Natl. Acad. Sci. USA* 93, 15209-15214.
- 16) Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, **Pellegata NS**, Gaudio M, Magni E, Vio A and Ranzani GN. (1997) Gene amplification and proliferative kinetics in relation to prognosis in gastric cancer. *Cancer* 79, 226-232.
- 17) **Pellegata NS**, Dieguez-Lucena JL, Joensuu T, Lau S, Montgomery KT, Krahe R, Kivela T, Kucherlapati R, Forsius H and de la Chapelle A. (2000) Mutation in KERA, encoding keratocan, cause cornea plana. *Nature Genet.* 25, 91-95.
- 18) Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, **Pellegata NS**, Plattner R, Stanbridge EJ, Cajot JF. (2000) p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. *Int J Cancer* 288, 685-91.
- 19) Scovassi AI, **Pellegata NS**, Di Stefano L, Padovan L, Negri C, Prosperi E, Riva F, Ciomei M and Ranzani GN. (2001) Effects of Topoisomerase II inhibitors on gastric cancer cell lines characterized by different genetic lesions. *Anticancer Res.* 21, 2803-8.
- 20) Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, **Pellegata NS** and de la Chapelle A. (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. *Proc. Natl. Acad. Sci. USA* 98, 15044-9.
- 21) Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, De La Chapelle A, **Pellegata NS**. (2002) Gene expression profiling of isogenic cells with different *TP53* gene dosage reveals numerous genes that are affected by *TP53* dosage and identifies *CSPG2* as a direct target of p53. *Proc. Natl. Acad. Sci. U S A* 99, 15632-7.
- 22) Huang Y., de la Chapelle A. and **Pellegata N.S.** (2003) Hypermethylation, but not LOH, is associated with the low expression of *MT1G* and *CRABP1* in papillary thyroid carcinoma. *Int J Cancer* 104, 735-744.
- 23) Piotrowska K, **Pellegata NS**, Rosemann M, Fritz A, Graw J and Atkinson J. (2004) Mapping of a Novel MEN-like Syndrome Locus to Rat Chromosome 4. *Mammalian Genome* 15, 135-141.
- 24) Prasad ML, **Pellegata NS**, Kloos RT, Barbacioru C, Huang Y, de la Chapelle A. (2004) CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study. *Thyroid* 14, 169-75.
- 25) Prasad ML, Huang Y, **Pellegata NS**, de la Chapelle A, Kloos RT. (2004) Hashimoto's thyroiditis with papillary



- thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. *Histopathology* 45, 39-46.
- 26) Aldred MA, Huang Y, Liyanarachchi S, **Pellegata NS**, Gimm O, Jhiang S, Davuluri RV, de la Chapelle A, Eng C. (2004) Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. *J Clin Oncol.* 22, 3531-9.
  - 27) Prasad ML, **Pellegata NS**, Huang Y, Nagaraja HN, Chapelle Ad A, Kloos RT. (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. *Mod Pathol* 18, 48-57.
  - 28) **Pellegata NS**, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ. (2006) Germline mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and man. *Proc Natl Acad Sci USA* 2006, 103:15558-63.
  - 29) Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, **Pellegata N**, de la Chapelle A. (2007) Identification of a novel noncoding RNA gene, NAMA that is downregulated in papillary thyroid carcinoma with BRAF mutation, and associated with growth arrest. *Int J Cancer*, 15: 767-75.
  - 30) **Pellegata NS**, Quintanilla-Martinez L, Keller G, Liyanarachchi S, Höfler H, Atkinson MJ and Fend F. (2007) Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutation and rarely with deletions. *Virchows Archiv*, 451:37-46.
  - 31) Bhardwaj A, Frankel WL, **Pellegata NS**, Wen P, Prasad ML. (2008) Versican expression in tumors - a tissue microarray-based study. *Appl Immunohistochem Mol Morphol*, 16:263-6.
  - 32) Henopp T, Anlauf M, Schmitt A, Schlenger R, Zalatnai A, Couvelard A, Ruzsniowski P, Schaps KP, Jonkers YM, Speel EJ, **Pellegata NS**, Heitz PU, Komminoth P, Perren A, Klöppel G. (2009 ) Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas. *J Clin Endocrinol Metab*, 94:213-217.
  - 33) Noll S, Hampp G, Bausbacher H, **Pellegata NS**, Kranz H. (2009) Site-directed mutagenesis of multi-copy-number plasmids: Red/ET recombination and unique restriction site elimination. *BioTechniques*, 46: 527–533.
  - 34) Shyla A, Hölzlwimmer G, Calzada-Wack J, Bink K, Tischenko O, Guilly M-N, Chevillard S, Samson E, Graw J, Atkinson MJ and **Pellegata NS**. (2010) Allelic loss of chromosomes 8 and 19 in MENX-associated rat pheochromocytoma. *Int. J. Cancer*, 126:2362-72.
  - 35) Molatore S, Kiermaier E, Jung CB, Pulz E, Höfler H, Atkinson MJ and **Pellegata NS**. (2010) Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. *Mol Cancer*, 9:116.
  - 36) Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, Zatelli MC, **Pellegata NS**. (2010) A novel germline p27 mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. *Hum Mutat*, 31:E1825-35.
  - 37) Molatore S, Liyanarachchi S, Irmeler M, Perren A, Mannelli M, Ercolino T, Beuschlein F, Jarzab B, Wloch J, Ziaja J, Zoubaa S, Neff F, Beckers J, Höfler H, Atkinson MJ, **Pellegata N.S.** (2010) MENX-associated pheochromocytoma shares gene expression patterns with human pheochromocytoma. *Proc Natl Acad Sci USA* 107:18493-8.
  - 38) Costa-Guda J, Marinoni I, Molatore S, **Pellegata NS**, Arnold A. (2011) Germline and Somatic Mutations of *CDKN1B* in Sporadic Parathyroid Adenomas. *J Clin Endocrin Metab*, 96:E701-6.
  - 39) Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, **Pellegata NS**. (2011) Levels of p27 sensitize to dual PI3K/mTOR inhibition. *Mol Cancer Ther.* 10:1450-9.
  - 40) Miederer M, Molatore S, Marinoni I, Perren A, Spitzweg C, Reder S, Wester H-J, Buck AK, Schwaiger M, **Pellegata NS**. (2011) Functional Imaging of Pheochromocytoma with <sup>68</sup>Ga-DOTATOC and <sup>11</sup>C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia. *Int J Mol Imaging*;175352.
  - 41) Waser B, Beetschen K, **Pellegata NS**, Reubi JC. (2011) Incretin receptors in non-neoplastic and neoplastic thyroid C-cells in rodents and humans: relevance for incretin-based diabetes therapy. *Neuroendocrinology*, 94:291-301.
  - 42) Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea M-L, Theodoropoulou M, Rodien P, Naves LA, Rohmer V, Estour B, Lecomte P, Borson-Chazot F, Penfornis A, Yaneva M, Guitelman M, Casterman E, Verhaege C, Wémeau J-L, Tabarin A, Caron P, Fajardo Montañana C, Delemer B, Archambeaud F, Zacharieva S, Brue T, Enjalbert A, Bours V, **Pellegata NS** and Beckers A. Cyclin dependent

- kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds. (2012) *Endocr Relat Cancer*, 19:233-41.
- 43) Lee M, Waser B, Reubi JC, **Pellegata NS**. (2012) Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway. *Mol Endo*, 26:1394-405.
- 44) Marinoni I, Lee M, Mountford S, Perren A, Bravi I, Jennen L, Feuchtinger A, Roncaroli F, **Pellegata NS**. Characterization of MENX-associated pituitary tumors. (2013) *Neuropath App Neurobiol*, 39:256-69.
- 45) Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S, Ferasin S, Cetani F, Pardi E, Korbonits M, **Pellegata NS**, Sidarovich V, Quattrone A, Opocher G, Mantero F, Scaroni C. (2013) A Novel Mutation in the Upstream Open Reading Frame of the *CDKN1B* Gene Causes MEN4 Phenotype. *PLOS Genetics*, 9:e1003350.
- 46) Lee M, **Pellegata NS**. (2013) Folate receptor-mediated drug targeting: a possible strategy for nonfunctioning pituitary adenomas? *Endocrinology*, 154:1387-9.
- 47) Lee M, Marinoni I, Irmeler I, Psaras T, Honegger JB, Beschorner R, Anastasov N, Beckers J, Theodoropoulou M, Roncaroli F, **Pellegata NS**. (2013) Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. *Acta Neuropathol*, 126:137-50.
- 48) Gaertner FC, Wiedemann T, Yousefi BH, Lee M, Repokis I, Higuchi T, Nekolla SG, Yu M, Robinson S, Schwaiger M, **Pellegata NS**. (2013) Preclinical evaluation of [<sup>18</sup>F]LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. *J Nucl Med*, 54:2111-7.
- 49) Sekiya T, Bronstein MD, Benfini K, Longuini VC, Jallad RS, Machado MC, Goncalves TD, Osaki LH, Higashi L, Viana J Jr, Kater C, Lee M, Molatore S, Francisco G, Chammas R, Naslavsky MS, Schlesinger D, Gama P, Duarte YAO, Lebrão ML, Zatz M, Meirelles O, Liberman B, Fragoso MCBV, Toledo SPA, **Pellegata NS**, Toledo RA. (2014) p27 variant and corticotropinoma susceptibility: a genetic and in vitro study. *Endocr Relat Cancer*, 21:395-404.
- 50) Longuini VC, Lourenco DM, Sekiya T, Meirelles O, Goncalves TD, Coutinho FL, Francisco G, Osaki LH, Chammas R, Alves VAF, Siqueira SAC, Schlesinger D, Naslavsky MS, Zatz M, Duarte YAO, Lebrão ML, Gama P, Lee M, Molatore S, Pereira MAA, Jallad RS, Bronstein MD, Cunha-Neto MB, Liberman B, Fragoso MCBV, Toledo SPA, **Pellegata NS**, Toledo RA. (2014) Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutations. *European J Endocrinol*, 171:335-42.
- 51) Pardi E, Mariotti S, **Pellegata NS**, Benfini K, Borsari S, Saponaro F, Torregrossa L, Cappai A, Satta C, Mastinu M, Marcocci C, Cetani F. (2014) Functional characterization of a CDKN1B mutation in a Sardinian 1 kindred with 2 multiple endocrine neoplasia type 4 (MEN4). *Endocrine Connections*, Nov 21 [Epub ahead of print].
- 52) Lee M, Lupp A, Mendoza N, Martin N, Beschorner R, Honegger J, Schlegel J, Shively T, Pulz E, Schulz S, Roncaroli F, **Pellegata NS**. (2014) Somatostatin receptor 3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. *Endocr Relat Cancer*, 22:111-9.
- 53) Chin SO, Hwang JK, Rhee SY, Chon S, Oh S, Lee M, **Pellegata NS**, Kim SW. (2015) Acromegaly due to a Macroinvasive Plurihormonal Pituitary Adenoma and a Rectal Carcinoid Tumor. *Endocrinol Metab* (Seoul), Jan 5 [Epub ahead of print]
- 54) Vukicevic V, Fernandez Rubin de Celis M, **Pellegata NS**, Bornstein SR, Androutsellis-Theotokis A, Ehrhart-Bornstein M. (2015) Adrenomedullary Progenitor Cells: Isolation and Characterization of a Highly Potent Stem Cell Population. *Mol. Cell. Endocrinol*, 408:178-184.
- 55) Miras AD, Mogford J, Wright J, Mendoza NN, Xekouki P, Lakhani A, **Pellegata NS**, Stratakis C, Roncaroli F, Russell-Jones D. (2015) Ovarian hyperstimulation from ectopic FSH hypersecretion. *The Lancet*, 385:392.
- 56) Sambugaro S, Di Ruvo M, Ambrosio MR, Tagliati F, **Pellegata NS**, degli Uberti E, Zatelli MC. (2015) Early onset acromegaly associated with a new *CDKN1B* promoter deletion. *Endocrine*, 49:58-64.
- 57) Wester HJ, Keller U, Beer AJ, Schottelius M, Philipp-Abbrederis K, Hoffmann F, Šimeček J, **Pellegata NS**, Rudelius M, Kessler H, Schwaiger M. (2015) Disclosing the CXCR4 receptor expression in lymphoproliferative diseases by targeted molecular imaging. *Theranostics*, 5: 618-630.
- 58) Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong CS, JCaberg J-H,

- Verrua E, Naves LA, Cheetham TD, Young J, Lysy PA, Petrossians P, Cotterill A, Shah NS, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barra GB, Casulari LA, Neggers SJ, Salvatori R, Jaffrain-Rea M-L, Zacharin M, Santamaria BL, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, T Collins MT, Bonneville J-F, Quezado M, Chittiboina P, Oldfield EH, Bours V, Liu P, De Herder W, **Pellegata NS**, Lupski JR, Daly AF, Stratakis CA. (2015) X-linked Acrogigantism (X-LAG) Syndrome: Clinical Profile and Therapeutic Responses. *Endocrine Related Cancer*, 22:353-67.
- 59) Lee M, Wiedemann T, Gross C, Roncaroli F, Braren R, **Pellegata NS**. (2015) Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. *Clinical Cancer Research*, 21:3204-3215.
- 60) van Berkel A, Rao JU, Lenders JWM, **Pellegata NS**, Kusters B, Piscaer I, Hermus ARMM, Plantinga TS, Langenhuijsen JF, Vriens D, Janssen MJR, Gotthardt M, Timmers HJLM. (2015) Semi-quantitative 123I-metaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma from physiological adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. *J Nucl Med*, 56:839-46.
- 61) Hrabě de Angelis M, .... **Pellegata NS**, ...Brown S. (2015) Deciphering mammalian gene function through broad based phenotypic screens across a consortium of mouse clinics. *Nature Genetics*, Epub Jul 27.
- 62) Leinhäuser I, Richter A, Lee M, Höfig I, Anastasov N, Fend F, Ercolino T, Mannelli M, Gimenez-Roqueplo AP, Robledo M, de Krijger R, Felix Beuschlein F, Michael J, Atkinson MJ, **Pellegata NS**. (2015) Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. *OncoTarget*, Epub Jul 31.
- 63) Wiedemann T, Bielohuby M, Müller TD, Bidlingmaier M, **Pellegata NS**. (2015) Obesity in MENX rats is accompanied by high circulating levels of ghrelin and improved insulin sensitivity. *Diabetes*, Epub Oct 28.
- 64) Naves LA, Daly AF, Dias LA, Yuan B, Oliveira Zakir JC, Barcellos Barra G, Palmeira L, Villa C, Trivellin G, Jreige A Jr, Cavalcante Neto FF, Liu P, **Pellegata NS**, Stratakis CA, Lupski JR, Beckers A. (2015) Aggressive tumor growth and clinical evolution in a patient with X-linked acrogigantism syndrome. *Endocrine*, Epub Nov 25.
- 65) Wiedemann T, Peitzsch M, Qin N, Neff F, Ehrhart-Bornstein M, Eisenhofer G, **Pellegata NS**. Morphology, biochemistry and pathophysiology of MENX-related pheochromocytoma recapitulate the clinical features. *Endocrinology*, In Revision.

#### INVITED REVIEWS AND BOOK CHAPTERS

- 66) **Pellegata NS** and Ranzani GN. (1996) The significance of *p53* mutations in human cancers. *Eur. J. Histochem.*, 40: 273-282.
- 67) Molatore S and **Pellegata NS** "The MENX syndrome and p27: relationships with multiple endocrine neoplasia" in *Progress in Brain Research: Neuroendocrinology 2010*.
- 68) Marinoni I and **Pellegata NS**. (2010) p27, a novel MEN gene? *Neuroendocrinology*, 93: 19-28.
- 69) **Pellegata NS** (2012) MENX and MEN4. *Clinics*, 67: Suppl 1:13-8.
- 70) **Pellegata NS** (2012) MENX. *Annales d'Endocrinologie*, 73:65-70.
- 71) Lee M and **Pellegata NS** "MEN4" in *Genetic Endocrine Tumor Syndromes, Frontiers of Hormone Research*, Ed. C. Stratakis, 2013; 41:63-78.
- 72) Lee M. and **Pellegata NS** (2013) Multiple endocrine neoplasia syndromes associated with mutation of p27. *J Endocrinol Invest.* 36:781-7.
- 73) Wiedemann T and **Pellegata NS**. (2015) Animal models of multiple endocrine neoplasia. *Mol Cell Endocr*, S0303-7207:30013-7.

#### Scholar Metrics (source: Scopus, October 2015):

**N.S. Pellegata: 2682 citations; h-index 24.**